Barclays Downgrades Cardiome Pharma (CRME) to Equalweight

February 7, 2011 7:49 AM EST Send to a Friend
Barclays downgraded Cardiome Pharma (NASDAQ: CRME) from Overweight to Equalweight. PT ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login